The latest update is out from Tempus Resources Ltd. ( (AU:SMM) ).

Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.

Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and ...

Tempus AI, Inc. remains a Buy with operational performance and partnerships strengthening the long-term thesis. Learn more ...

Tempus has a projected earnings growth rate of 58.9% for 2025, higher than the industry’s 37% growth. The company has a ...

Fintel reports that on December 15, 2025, JP Morgan maintained coverage of Tempus AI (NasdaqGS:TEM) with a Neutral ...

Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Little Rock-based real estate investment trust Tempus Realty Partners has acquired a nearly 20-acre site in a Charlotte, N.C., suburb that it plans to develop into a 150,000-square-foot warehouse, the ...

Tempus AI Inc. reported its third-quarter 2025 earnings, surpassing expectations with a narrower-than-anticipated loss per share and higher revenue, yet the company’s stock fell in aftermarket trading ...